Syros is focused on developing medicines for cancer and immune-mediated diseases with the potential to provide a profound and durable benefit for currently underserved patients.

We are building a pipeline of gene control medicines. Our lead pipeline program SY-1425, an oral, potent and selective RARa agonist that we are initially developing in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), is currently in a Phase 2 clinical trial. Our second most advanced program is SY-1365, a highly potent and selective small molecule inhibitor of CDK7 that we expect to advance into a Phase 1 clinical trial in the first half of 2017 in patients with transcriptionally driven solid tumors and acute leukemias. Both of these programs may have potential in additional diseases. Using our platform, we are also generating a pipeline of novel drug candidates in earlier stages of research and development for genomically defined subsets of patients.

To support the development of our pipeline, we have analyzed and continue to analyze gene expression programs in multiple therapeutic areas and diseases. To date, we have identified many novel drug targets in oncology, immuno-oncology and autoimmune diseases and validated several of these targets using biological methods to knock out the target gene or chemical methods to modulate the target’s activity. Our long-term goal is to analyze gene expression programs in a number of additional therapeutic areas and serious diseases where we believe currently underserved patients can benefit from gene control medicines.



Syros has adopted a policy that describes the guidelines by which it will consider requests for access to one of its investigational products outside of a clinical trial.  You can review that policy here.